Drugs / CAR2 Anti-CD38 A2 CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03464916 | Oct 2018 → Aug 2020 | refractory plasma cell neoplasm | Sorrento Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR2 Anti-CD38 A2 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03464916 ↗ |
| Modality | Cell therapy | “CAR2 Anti-CD38 A2 CAR-T Cells” NCT03464916 ↗ |
| Route | Intravenous | “Autologous IV infusion” NCT03464916 ↗ |
| Target | CD38 | “Anti-CD38” NCT03464916 ↗ |